Genomically-guided therapies: a new era for cystic fibrosis

M. Mall (Berlin, Germany)

Source: Virtual Congress 2020 – European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Mall (Berlin, Germany). Genomically-guided therapies: a new era for cystic fibrosis. Virtual Congress 2020 – European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Update on new treatments for cystic fibrosis
Source: Virtual Congress 2020 – Updates in cystic fibrosis
Year: 2020


Cystic fibrosis: prospects for therapy of some class 1 mutations
Source: Annual Congress 2007 - Cystic fibrosis: will the new biology deliver?
Year: 2007


Revisiting α1-antitrypsin therapy in cystic fibrosis: can it still offer promise?
Source: Eur Respir J 2007; 29: 229-230
Year: 2007


Novel therapeutics for cystic fibrosis
Source: ERS Webinar 2020: Novel therapeutics for cystic fibrosis
Year: 2020


The need for lung transplantation in cystic fibrosis (CF) in the era of new treatment
Source: Virtual Congress 2020 – Lung transplantation in the era of new drugs
Year: 2020


CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways
Source: Eur Respir Rev, 29 (156) 190068; 10.1183/16000617.0068-2019
Year: 2020



New cystic fibrosis therapy targets
Source: Research Seminar 2014 - Protein quality control in lung disease
Year: 2014

Health-economic aspects of cystic fibrosis screening and therapy
Source: Eur Respir Monogr 2014; 64: 304-319
Year: 2014


Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: 693-703
Year: 2005



Genotype specific therapies for cystic fibrosis
Source: Annual Congress 2004 - New approaches to cystic fibrosis: from cells and molecules to novel therapies
Year: 2004

A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials
Source: Eur Respir J 2015; 46: 243-249
Year: 2015



Genotype-specific small-molecule therapy for cystic fibrosis
Source: Breathe 2013; 9: 176-186
Year: 2013


New vaccines for use in cystic fibrosis
Source: Annual Congress 2004 - New approaches to cystic fibrosis: from cells and molecules to novel therapies
Year: 2004

Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis
Source: Eur Respir J, 51 (6) 1702457; 10.1183/13993003.02457-2017
Year: 2018



Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard
Source: Eur Respir J 2015; 45: 1208-1210
Year: 2015


The treatment burden of cystic fibrosis: a day-to-day experience with treatment as someone with cystic fibrosis
Source: Breathe, 17 (1) ; 10.1183/20734735.0013-2021
Year: 2021



New horizons for cystic fibrosis gene and cell therapy
Source: Eur Respir Monogr 2014; 64: 150-168
Year: 2014